Vladimir Maletic, MD

Efficacy of adjunctive cariprazine across individual depressive symptoms in major depressive disorder: a post-hoc analysis

Abstract: Background: Patients with major depressive disorder (MDD) who have inadequate response to antidepressant treatment (ADT) may require adjunctive therapy. Cariprazine (CAR), a dop...

Sneh Mody ;

Vladimir Maletic , MD;

01/19/2023

Efficacy of Adjunctive Cariprazine on Anxiety Symptoms in Patients With Major Depressive Disorder and Baseline Anxiety: Post Hoc Analysis of a Randomized Controlled Trial

Abstract: Background: Adjunctive cariprazine was evaluated in patients with major depressive disorder (MDD) and inadequate response to monotherapy antidepressant treatment (ADT), stratifi...

Vladimir Maletic , MD;

Leslie Citrome , MD;

01/19/2023

Videos

Conclusion: Navigating Setbacks to School—A Complex Pediatric Case Study

08/07/2023

Vladimir Maletic , MD;

Vladimir Maletic MD, MS, discusses his case presentation "Navigating Setbacks to School: A Complex Pediatric Case Study."

Vladimir Maletic MD, MS,...

08/07/2023

Psych Congress Network

Videos

Emerging Research and Technology: Beyond One-Size-Fits-All Medicine

12/04/2023

Vladimir Maletic , MD;

Dr Maletic discusses how new research shows promise for advancing our comprehension of brain networks, circuits, and neurotransmitters to benefit those with neurological and psychiatric disorders

Dr Maletic discusses how new...

12/04/2023

Psychiatry & Behavioral Health

Videos

Beyond Neurotransmitters: Unraveling the Brain Circuitry of Mental Health

11/27/2023

Vladimir Maletic , MD;

Vladimir Maletic, MD, explores the complexities of brain circuitry and the neurobiological basis of major psychiatric conditions.

Vladimir Maletic, MD, explores...

11/27/2023

Psychiatry & Behavioral Health

Efficacy of Cariprazine in Patient Subgroups: Post Hoc Analysis of 3 Randomized, Placebo-Controlled Trials in Patients With Bipolar Depression

Introduction: Cariprazine is a dopamine D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist approved to treat bipolar depression. The efficacy of cariprazine in patients wit...

Vladimir Maletic , MD;

Lakshmi Yatham , MBBS, FRCPC, MRCP, MBA;

Rakesh Jain , MD, MPH, RD;

Willie Earley , MD;

Mehul Patel , MD, PharmD;

Mauricio Tohen , MD, DrPH, MBA;

10/08/2020